PL2549995T3 - Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny - Google Patents
Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabinyInfo
- Publication number
- PL2549995T3 PL2549995T3 PL11714880T PL11714880T PL2549995T3 PL 2549995 T3 PL2549995 T3 PL 2549995T3 PL 11714880 T PL11714880 T PL 11714880T PL 11714880 T PL11714880 T PL 11714880T PL 2549995 T3 PL2549995 T3 PL 2549995T3
- Authority
- PL
- Poland
- Prior art keywords
- anatabine
- methods
- synthesizing
- treat inflammation
- inflammation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/729,346 US8207346B2 (en) | 2010-03-23 | 2010-03-23 | Methods of synthesizing anatabine |
| US38381110P | 2010-09-17 | 2010-09-17 | |
| US38444710P | 2010-09-20 | 2010-09-20 | |
| US201161439473P | 2011-02-04 | 2011-02-04 | |
| US201161439483P | 2011-02-04 | 2011-02-04 | |
| PCT/US2011/029613 WO2011119722A2 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
| EP11714880.9A EP2549995B1 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2549995T3 true PL2549995T3 (pl) | 2021-09-27 |
Family
ID=44201080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11714880T PL2549995T3 (pl) | 2010-03-23 | 2011-03-23 | Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP2549995B1 (pl) |
| AU (5) | AU2011232478A1 (pl) |
| CA (1) | CA2794097C (pl) |
| DK (1) | DK2549995T3 (pl) |
| ES (1) | ES2869851T3 (pl) |
| PL (1) | PL2549995T3 (pl) |
| PT (1) | PT2549995T (pl) |
| WO (1) | WO2011119722A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012302257A1 (en) * | 2011-08-29 | 2014-03-13 | Rcp Development, Inc. | Products for anti-inflammation support |
| EP2793026A1 (en) | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| AU2019407661A1 (en) | 2018-12-17 | 2021-04-29 | Philip Morris Products S.A. | 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof |
| KR20230024889A (ko) | 2020-06-15 | 2023-02-21 | 필립모리스 프로덕츠 에스.에이. | 아나타빈 분말 조성물 |
| US20230301919A1 (en) | 2020-09-03 | 2023-09-28 | Philip Morris Products S.A. | Freeze dried low hygroscopicity active powder compositions |
| US20230346696A1 (en) | 2020-09-03 | 2023-11-02 | Philip Morris Products S.A. | Spray dried low hygroscopicity active powder compositions |
| KR20230061366A (ko) | 2020-09-03 | 2023-05-08 | 필립모리스 프로덕츠 에스.에이. | 저 흡습성 활성 분말 조성물 |
| CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
| WO2023117661A1 (en) | 2021-12-20 | 2023-06-29 | Philip Morris Products S.A. | Increasing anatabine in tobacco leaf by regulating methyl putrescine oxidase |
| CN115594662A (zh) * | 2022-10-19 | 2023-01-13 | 昆明理工大学（Cn） | 一种(s)-烟碱的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| DE4002784C1 (pl) | 1990-01-31 | 1991-04-18 | B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De | |
| US5065775A (en) | 1990-02-23 | 1991-11-19 | R. J. Reynolds Tobacco Company | Tobacco processing |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| EP1083913A4 (en) * | 1998-06-05 | 2004-03-17 | Regent Court Technologies | MONOAMINE OXIDASE (MAO) INHIBITORS AND USES THEREOF |
| WO2001094951A2 (en) * | 2000-06-08 | 2001-12-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-reactive protein induced inflammation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| JP5179011B2 (ja) | 2002-10-09 | 2013-04-10 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | 胎盤虚血および多臓器不全のモニタリング |
| ES2439229T3 (es) | 2004-10-06 | 2014-01-22 | The Brigham And Women's Hospital, Inc. | Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento |
| US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
| US8841329B2 (en) * | 2008-09-11 | 2014-09-23 | Dignity Health | Nicotinic attenuation of CNS inflammation and autoimmunity |
| US8151804B2 (en) | 2008-12-23 | 2012-04-10 | Williams Jonnie R | Tobacco curing method |
-
2011
- 2011-03-23 CA CA2794097A patent/CA2794097C/en active Active
- 2011-03-23 ES ES11714880T patent/ES2869851T3/es active Active
- 2011-03-23 AU AU2011232478A patent/AU2011232478A1/en not_active Abandoned
- 2011-03-23 PT PT117148809T patent/PT2549995T/pt unknown
- 2011-03-23 PL PL11714880T patent/PL2549995T3/pl unknown
- 2011-03-23 WO PCT/US2011/029613 patent/WO2011119722A2/en active Application Filing
- 2011-03-23 EP EP11714880.9A patent/EP2549995B1/en active Active
- 2011-03-23 EP EP19162452.7A patent/EP3524245A1/en not_active Withdrawn
- 2011-03-23 EP EP19162458.4A patent/EP3524246A1/en not_active Withdrawn
- 2011-03-23 EP EP21165632.7A patent/EP3871674A1/en active Pending
- 2011-03-23 DK DK11714880.9T patent/DK2549995T3/da active
-
2017
- 2017-03-08 AU AU2017201593A patent/AU2017201593C1/en active Active
-
2019
- 2019-01-08 AU AU2019200103A patent/AU2019200103B2/en active Active
- 2019-01-08 AU AU2019200102A patent/AU2019200102B2/en active Active
-
2020
- 2020-10-21 AU AU2020257090A patent/AU2020257090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017201593A1 (en) | 2017-03-30 |
| AU2020257090B2 (en) | 2021-12-02 |
| AU2019200103A1 (en) | 2019-01-31 |
| EP3524245A1 (en) | 2019-08-14 |
| PT2549995T (pt) | 2021-07-29 |
| EP3524246A1 (en) | 2019-08-14 |
| AU2020257090A1 (en) | 2020-11-19 |
| AU2019200102B2 (en) | 2020-07-30 |
| EP3871674A1 (en) | 2021-09-01 |
| AU2019200102A1 (en) | 2019-01-31 |
| EP2549995A2 (en) | 2013-01-30 |
| WO2011119722A3 (en) | 2011-12-29 |
| AU2017201593B2 (en) | 2019-02-28 |
| WO2011119722A2 (en) | 2011-09-29 |
| ES2869851T3 (es) | 2021-10-26 |
| DK2549995T3 (da) | 2021-05-25 |
| AU2011232478A1 (en) | 2015-11-19 |
| CA2794097C (en) | 2016-08-09 |
| CA2794097A1 (en) | 2011-09-29 |
| AU2019200103B2 (en) | 2020-07-30 |
| EP2549995B1 (en) | 2021-04-21 |
| AU2017201593C1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2549995T (pt) | Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina | |
| HK1168349A1 (en) | Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture | |
| EP2611413A4 (en) | SKIN COMPOSITIONS AND THEIR APPLICATIONS | |
| EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
| HK1199828A1 (en) | Compositions and methods for stimulating magp-1 to improve the appearance of skin magp-1 | |
| SG10201602752XA (en) | Melanin modification compositions and methods of use | |
| EP2536756A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| PL2448581T3 (pl) | Kompozycje terapeutyczne i odnośne sposoby ich stosowania | |
| EP2584897A4 (en) | COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE | |
| EP2629782A4 (en) | USE OF EXOSOMES TO ACTIVATE OR AMPLIFY HAIR GROWTH | |
| IL221476A0 (en) | Methods and compositions to treat hemorrhagic conditions of the brain | |
| HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
| EP2544655A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| EP2480579A4 (en) | METHODS OF TREATING INFLAMMATION | |
| IL256026A (en) | Treatment methods | |
| IL232135A0 (en) | Therapeutic combinations and methods for treating melanoma | |
| IL229968A0 (en) | Tetrazolyloxy derivatives and methods for their production | |
| EP2755668A4 (en) | COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH | |
| EP2635293A4 (en) | HEALING COMPOSITIONS FOR SKIN WOUND AND USE METHOD THEREFOR | |
| GB201115521D0 (en) | Colorant-polyesters and methods of producing colorant-polyesters | |
| ZA201408057B (en) | Compositions and methods for the treatment of moderate to severe pain | |
| EP2553089A4 (en) | CELL THERAPY TO IMPROVE WOUND HEALING AND ASSOCIATED COMPOSITIONS AND METHODS | |
| PL2609156T3 (pl) | Kompozycje zmniejszające opór przepływu i sposoby ich wytwarzania i zastosowanie | |
| EP2558113A4 (en) | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE |